SecBot SecBot
8-K ·Filed Sep 4, 2026

IONS

IONIS PHARMACEUTICALS INC
BULLISH
Impact 7/10
Horizonweeks Processed2mo ago SEC0001140361-26-035657
8-K context-dependent: Items 7.01, 8.01
Actionable Insight ▲ Bullish

Monitor initial U.S. launch uptake and prescription trends for ZANVASTRO over the next 2–4 quarters. The PRV could be sold for a one-time cash infusion. Watch for Recordati's regulatory filings in Europe and Japan in 2027, which could expand the addressable market.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$58.09
T+0 close · Sep 4, 2026 · via day close
Latest settled
−25.12%
T+20 · $43.50 · next T+60 in 14d
Vs SPY
−25.72%
α at T+20
Latest observation
−47.27%
T+49 · FF3 residual α
  1. T+0 · Sep 4 $58.09entry
  2. T+1 · 2mo ago −2.38%α −1.83% · $56.71
  3. T+5 · 2mo ago −11.45%α −10.24% · $51.44
  4. T+20 · 6w ago −25.12%α −25.72% · $43.50
  5. T+50 · todayOpen
  6. T+60 · in 14d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ionis Pharmaceuticals announced FDA approval of ZANVASTRO (zilganersen) as the first and only disease-modifying treatment for Alexander disease (AxD), an ultra-rare progressive neurological disorder. The approval is based on a pivotal study that met its primary endpoint of gait speed stabilization (p=0.041), and Ionis also received a Priority Review Voucher. This marks Ionis's first independent launch from its neurology pipeline and adds a new revenue stream.

Key Facts

  • FDA approved ZANVASTRO (zilganersen) for Alexander disease in pediatric and adult patients on September 3, 2026.
  • ZANVASTRO is the first and only disease-modifying treatment for AxD, an ultra-rare disorder affecting ~1 in 1–3 million people.
  • Pivotal study met primary endpoint: stabilization of gait speed at Week 61 (least square mean difference 33.3%, p=0.041).
  • Ionis received a Rare Pediatric Disease Priority Review Voucher (PRV) with the approval.
  • ZANVASTRO will be available in the U.S. in the coming weeks; Recordati holds ex-U.S. rights with EU/Japan submissions expected in 2027.
  • This is Ionis's first independent launch from its neurology pipeline and second independent launch in 2026.

Financial Impact

New revenue stream from ultra-rare disease treatment; PRV historically valued at $100M+; no specific revenue guidance provided.

revenuepipeline credibility

Risk Factors

  • Ultra-rare disease limits peak revenue potential (AxD prevalence ~1 in 1–3 million).
  • Safety label includes aseptic meningitis warning, which may impact adoption.
  • Commercial execution risk as Ionis's first independent launch.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
78% bullish (32 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-035657
Document: ef20081649_ex99-1.htm0001140361-26-035657
Document: 0001140361-26-035657-index-headers.html0001140361-26-035657
Document: 0001140361-26-035657-index.html0001140361-26-035657
Document: 0001140361-26-035657.txt0001140361-26-035657

Track record

26 reports on IONS

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +32.25% at T+60 after the Jul 9, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 9, 20267d ago 8-K Bearish 6/10 Entry $31.00 to $28.01 Now $28.01 +9.65% ▲ +9.65% +7.95% vs SPY
  2. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $44.90 to $40.15 Now $28.01 −37.62% ▼ −10.58% −9.87% vs SPY
  3. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $42.93 to $43.52 Now $28.01 −34.75% ▲ +1.37% +1.93% vs SPY
  4. Oct 21, 202626d ago 8-K Bullish 7/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
  5. Oct 21, 202626d ago Institutional Cluster Mixed 3/10 Entry $43.91 to $44.39 Now $28.01 −36.21% ▲ +1.09% +0.39% vs SPY
  6. Sep 23, 20267w ago 8-K Bullish 7/10 Entry $43.93 to $44.65 Now $28.01 −36.24% ▲ +1.64% +2.31% vs SPY
  7. Sep 4, 202610w ago 8-K Bearish 7/10 Entry $56.71 to $47.25 Now $28.01 +50.61% ▲ +16.68% +15.56% vs SPY
  8. Sep 4, 202610w ago 8-K Bullish 7/10 Viewing Entry $58.09 to $51.44 Now $28.01 −51.78% ▼ −11.45% −10.24% vs SPY
  9. Jul 31, 202615w ago Insider Buy Neutral 4/10 Entry $54.49 to $56.94 Now $28.01 −48.60% ▲ +4.50% +2.47% vs SPY
  10. Jul 29, 202615w ago 8-K Neutral 5/10 Entry $54.04 to $54.19 Now $28.01 −48.17% ▲ +0.28% −5.25% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens Wed (10h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 4, 2026